AbbVie, Phase III and Parkinson's
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...
AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in ...
AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...
AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...
AbbVie Inc (ABBV) stock saw a decline, ending the day at $193.51 which represents a decrease of $-0.32 or -0.17% from the prior close of $193.83. The stock opened at $192.95 and touched a low of $191.
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
AbbVie on Thursday said a late-stage study of its recently acquired tavapadon drug candidate for the neurodegenerative disorder Parkinson's disease hit its key goals. AbbVie said tavapadon met the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback